Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers

ADHD Clinical Trial

— ADHDenic  

Official title:

Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02599571
• Other study ID #: Pro00066144
• Secondary ID: 1R01HD083404
• Status: Terminated
• Phase: N/A
• Start date: March 30, 2016
• Est. completion date: September 12, 2019

Study information

• Verified date: January 2020
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the impact of different nicotine levels in cigarettes with individuals who have ADHD.

Description:

The purpose of this study is to examine the effects of very low nicotine content (VLNC) cigarettes on smoking behavior, psychiatric symptoms and functioning, and acceptability and adverse outcomes in young adult smokers with ADHD. Participants will attend a screening session, 2 baseline sessions, 6 experimental sessions, and a 30 day follow-up visit. Participants will be asked to smoke only the study cigarettes that we provide for 6 weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 71
• Est. completion date: September 12, 2019
• Est. primary completion date: September 12, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Age 18 - 40

• Smoke an average of 5-40 cigarettes per day for at least 1 year

• Breath CO levels > 8 ppm (if = 8 ppm, then NicAlert Strip > 6)

• Primary diagnosis of ADHD, any subtype as assessed by the CAADID; T-Score > 65 on one of the DSM- V relevant scales (Inattentive Symptoms, Hyperactive-Impulsive Symptoms, Total Symptoms or ADHD Index) on the Self-Report version of the CAARS; Clinician Rated ADHD-RS score >24.

• Cognitive functioning > 80 as assessed by the KBIT-II

Exclusion Criteria:

• Intention to quit smoking in the next 30 days

• Currently seeking treatment for smoking cessation

• Currently using nicotine replacement therapies or other pharmacotherapies as cessation aid (intermittent use acceptable)

• A quit attempt in the past 30 days resulting in greater than 3 days of abstinence

• Using other tobacco products more than 9 days in the past 30 days

• Significant unstable medical conditions (any significant change in a serious medical condition occurring during the past 3 months including cardiovascular disease, COPD, and cancer, as determined by the study physician at each site)

• Significant unstable psychiatric conditions (any significant change in psychiatric symptoms during the past 3 months as determined by the study physician at each site)

• Any Axis I Psychiatric Disorder as assessed by the MINI that is significantly impairing and/or would contraindicate participation in the study

• Psychiatric medication changes in the past 3 months including new prescriptions, changes in dosages or discontinuation of medications

• Positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP (Marijuana will be tested for but will not be an exclusionary criterion, participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded, participants failing the toxicology screen will be allowed to re-screen once. These participants will need to be re-consented before being rescreened to ensure they have received adequate informed consent.)

• Breath alcohol level > 0.01 (Participants failing the breath alcohol screen will be allowed to re-screen once. These participants will need to be re-consented before being rescreened to ensure they have received adequate informed consent.)

• Current diagnosis of DSM alcohol or drug use disorder (except for nicotine)

• Pregnant, trying to become pregnant or breastfeeding

• Smoking 'roll your own cigarettes' exclusively

• Currently taking anticonvulsant medications including: Phenytoin [Brand Name:

Dilantin], Carbamazepine [Brand Name: Tegretol, Carbatrol, Equetro, Epitol], Oxcarbazepine [Brand Name: Trileptal], Primidone [Brand Name: Mysoline], Phenobarbital

• CO reading >80 ppm

• Systolic BP between 90 and 160 (If below 90 then asymptomatic. Participants failing for blood pressure will be allowed to re-screen once.)

• Diastolic BP between 50 and 100 (If below 50 then asymptomatic. Participants failing for blood pressure will be allowed to re-screen once.)

• Heart rate between 45 and 115 bpm (If below 45 then asymptomatic. Participants failing for heart rate will be allowed to re-screen once.)

• Indicating any suicidal ideation in the past month or suicide attempts in the past 10 years.

• Inability to independently read and comprehend the consent form and other written study materials and measures.

• Having participated in a research study during the past three months in which the participant: Smoked a cigarette that was not his/her usual brand cigarette for more than one day, used any tobacco products beyond normal use for more than one day, used any nicotine replacement products or smoking cessation medications for more than one day

• Any previous experience using SPECTRUM cigarettes

Related Conditions & MeSH terms

• ADHD
• Nicotine Dependence
• Tobacco Use Disorder

Intervention

Other:
• Very low nicotine content cigarettes
Cigarettes containing a reduced amount of nicotine
• Conventional nicotine content cigarettes
Cigarettes containing a normal amount of nicotine

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina
United States	University of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (4)

Lead Sponsor	Collaborator
Duke University	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Food and Drug Administration (FDA), University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of cigarettes smoked per day	Self-reported number of cigarettes smoked per day	Six weeks
Primary	Composite measure of influence of reduced nicotine content on ADHD symptoms measured by ADHD Rating Scale and Clinical Global Impressions Scale along with related measures of cognition measured by the N-Back Task and the Continuous Performance Test	Composite of ADHD symptom questionnaires, inhibitory control, working memory	Six weeks
Primary	Composite measure of outcomes associated with acceptability; withdrawal measured by the MNWS and compliance measured by Time-Line Follow-Back questionnaire and daily self-report cigarette use	Composite of study dropout, compliance, changes in physical health	Six weeks
Secondary	Measures of discomfort/dysfunction; withdrawal and depression	Withdrawal scale and depression measures	Six weeks
Secondary	Measures of other health-related behaviors; dependence measures	Drug and alcohol use questionnaires	Six weeks